Gapping down
In reaction to disappointing earnings/guidance: TEU -13.5%, CNTF -12.4%, EXPR -12.2%, KTOS -10.5%, (light volume), GCA -8.6%, SCLN -6%, DRC -5.8%, HRZN -2.9%, CZR -2.3%, (light volume), GMO -1.8%, MW -1.1%, .
M&A news: EXXI -6.5% (to acquire EPL for ~$39 per share).
Other news: GERN -60.9% (receives verbal notice from the FDA that its IND application for imetelstat has been placed on full clinical hold), FMCC -15.6% (volatility in early trade as participants continue to digest the Senate Housing Reform bill that led to sharp selloffs in these stocks yesterday), FNMA -13.2% (volatility in early trade as participants continue to digest the Senate Housing Reform bill that led to sharp selloffs in these stocks yesterday), MX -9.4% (Audit Committee of the Company's Board of Directors has determined that the Company incorrectly recognized revenue on certain transactions and as a result will restate its financial statements), DL -7.4% (prices follow-on public offering of an aggregate of 4 mln ADSs by the co and several selling shareholders at $21.00 per ADS), NOR -6.3% (disclosed that extraordinary weather production disruptions may result in a $0.03-0.04 increase in integrated cash cost per pound during Q1; announced secondary offering of 10 mln shares by Apollo Global Management), SDLP -4.4% (announced public offering of 10.4 mln common units), VIP -3.4% (announces investigation by SEC), QGEN -2.3% (announces Non-U.S. offer involving convertible notes ).
Analyst comments: SNTA -20.1% (downgraded to Sell from Hold at Stifel and downgraded to Underperform from Market Perform at BMO Capital Mkts), NWBO -6.8% (downgraded to Perform from Outperform at Oppenheimer), HRZN-2.9% (downgraded to Underperform from Mkt Perform at Keefe Bruyette), MSI -2.2% (downgraded to Sell from Neutral at Goldman), DRH -2% (downgraded to Underperform from Neutral at BofA/Merrill), FCEL -1.5% (downgraded to Market Perform at Cowen), AIG -1.3% (downgraded to Hold from Buy at Deutsche Bank), CHD -1.3% (downgraded to Neutral from Outperform at Credit Suisse)
M&A news: EXXI -6.5% (to acquire EPL for ~$39 per share).
Other news: GERN -60.9% (receives verbal notice from the FDA that its IND application for imetelstat has been placed on full clinical hold), FMCC -15.6% (volatility in early trade as participants continue to digest the Senate Housing Reform bill that led to sharp selloffs in these stocks yesterday), FNMA -13.2% (volatility in early trade as participants continue to digest the Senate Housing Reform bill that led to sharp selloffs in these stocks yesterday), MX -9.4% (Audit Committee of the Company's Board of Directors has determined that the Company incorrectly recognized revenue on certain transactions and as a result will restate its financial statements), DL -7.4% (prices follow-on public offering of an aggregate of 4 mln ADSs by the co and several selling shareholders at $21.00 per ADS), NOR -6.3% (disclosed that extraordinary weather production disruptions may result in a $0.03-0.04 increase in integrated cash cost per pound during Q1; announced secondary offering of 10 mln shares by Apollo Global Management), SDLP -4.4% (announced public offering of 10.4 mln common units), VIP -3.4% (announces investigation by SEC), QGEN -2.3% (announces Non-U.S. offer involving convertible notes ).
Analyst comments: SNTA -20.1% (downgraded to Sell from Hold at Stifel and downgraded to Underperform from Market Perform at BMO Capital Mkts), NWBO -6.8% (downgraded to Perform from Outperform at Oppenheimer), HRZN-2.9% (downgraded to Underperform from Mkt Perform at Keefe Bruyette), MSI -2.2% (downgraded to Sell from Neutral at Goldman), DRH -2% (downgraded to Underperform from Neutral at BofA/Merrill), FCEL -1.5% (downgraded to Market Perform at Cowen), AIG -1.3% (downgraded to Hold from Buy at Deutsche Bank), CHD -1.3% (downgraded to Neutral from Outperform at Credit Suisse)